William Vandergrift

Dr. William Vandergrift

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2021 in Epilepsy Research
Verified
Journal Article
Closed access
EGEzequiel Gleichgerrcht
Ezequiel Gleichgerrcht
AGAdam S. Greenblatt
Adam S. Greenblatt
TKTanja S. Kellermann
Tanja S. Kellermann
NRNathan Rowland
Nathan Rowland
WVWilliam Vandergrift
William Vandergrift
LBLeonardo Bonilha
Leonardo Bonilha

1 December 2016 in World Neurosurgery
Verified
Journal Article
Closed access
MAMohammed A. Alshareef
Mohammed A. Alshareef
ZAZayed Almadidy
Zayed Almadidy
TBTiffany Baker
Tiffany Baker
APArie Perry
Arie Perry
CWCynthia T. Welsh
Cynthia T. Welsh
WVWilliam Vandergrift
William Vandergrift

29 January 2025 in Cancers
Verified
Journal Article
Open access
PDF file
TEThomas Eckert
Thomas Eckert
MZM S Zobaer
M S Zobaer
JBJessica Boulos
Jessica Boulos
AAAngela Alexander-Bryant
Angela Alexander-Bryant
TBTiffany Gray Baker
Tiffany Gray Baker
NRNathan C. Rowland
Nathan C. Rowland
Background: Glioblastoma (GBM) is the most common primary malignant brain tumor, with fewer than 5% of patients surviving five years after diagnosis. The introduction of immune checkpoint inhibitors (ICIs), followed by chimeric antigen receptor (CAR) T-cell therapy, marked major advancements in oncology. Despite demonstrating efficacy in other blood and solid cancers, these therapies have yielded limited success in clinical trials for both newly diagnosed and recurrent GBM. A deeper understanding of GBM’s resistance to immunotherapy is essential for enhancing treatment responses and translating results seen in other cancer models. Objectives: In this review, we examine clinical trial outcomes involving ICIs and CAR-T for GBM patients and explore the evasive mechanisms of GBM and the tumor microenvironment. Findings and Discussion: Multiple clinical trials investigating ICIs in GBM have shown poor outcomes, with no significant improvement in progression-free survival (PFS) or overall survival (OS). Results from smaller case studies with CAR-T therapy have warranted further investigation. However, no large-scale trials or robust studies have yet established these immunotherapeutic approaches as definitive treatment strategies. Future research should shift focus from addressing the scarcity of functional T cells to exploiting the abundant myeloid-derived cells within the tumor microenvironment. Conclusions: Translating these therapies into effective treatments for glioblastoma in humans remains a significant challenge. The highly immunosuppressive nature of GBM and its tumor microenvironment continue to hinder the success of these innovative immunotherapeutic approaches. Targeting the myeloid-derived compartment may lead to more robust and sustained immune responses.

4 May 2024 in Epilepsy & Behavior
Verified
Journal Article
Closed access
JMJ. Preston Mercer
J. Preston Mercer
RSRussell S. Sobel
Russell S. Sobel
JWJeffrey E. Wessell
Jeffrey E. Wessell
WVWilliam Vandergrift
William Vandergrift
JEJonathan C. Edwards
Jonathan C. Edwards
ZCZeke M. Campbell
Zeke M. Campbell

30 March 2021 in Journal of Neuroimaging
Verified
Journal Article
Closed access
PDF file
MYMilad Yazdani
Milad Yazdani
JRJustin Reagan
Justin Reagan
MKMadison Kocher
Madison Kocher
MAMichael Antonucci
Michael Antonucci
JTJames Taylor
James Taylor
MSMaria Vittoria Spampinato
Maria Vittoria Spampinato

29 May 2023 in Journal of Neurosurgery: Case Lessons
Verified
Journal Article
Open access
BRBrandon Rogowski
Brandon Rogowski
AMAaron Miller
Aaron Miller
BSBrian F. Saway
Brian F. Saway
JWJeffrey Wessell
Jeffrey Wessell
NRNathan C. Rowland
Nathan C. Rowland
WVWilliam Vandergrift
William Vandergrift
BACKGROUND: The Responsive Neurostimulation (RNS) system is an implantable device for patients with drug-resistant epilepsy who are not candidates for resection of a seizure focus. As a relatively new therapeutic, the full spectrum of adverse effects has yet to be determined. A literature review revealed no previous reports of cerebral vasospasm following RNS implantation. OBSERVATIONS: A 35-year-old man developed severe angiographic and clinical vasospasm following bilateral mesial temporal lobe RNS implantation. He initially presented with concerns for status epilepticus 8 days after implantation. On hospital day 3, a decline in his clinical examination prompted imaging studies that revealed a left middle cerebral artery (MCA) stroke with angiographic evidence of severe vasospasm of the left internal carotid artery (ICA), MCA, anterior cerebral artery (ACA), and right ICA and ACA. Despite improvements in angiographic vasospasm after appropriate treatment, a thrombus developed in the posterior M2 branch, requiring mechanical thrombectomy. Ultimately, the patient was stabilized and discharged to a rehabilitation facility with residual cognitive and motor deficits. LESSONS: Cerebral vasospasm as a cause of ischemic stroke after uneventful RNS implantation is exceedingly rare, yet demands particular attention given the potential for severe consequences and the growing number of patients receiving RNS devices.